重组人脑利钠肽联合沙库巴曲缬沙坦治疗高血压急症合并急性心力衰竭的效果

Recombinant Human Brain Natriuretic Peptide Combined with Sacubitril Valsartan in the Treatment of HypertensiveEmergency Combined with Acute Heart Failure

目的:探讨重组人脑利钠肽联合沙库巴曲缬沙坦治疗高血压急症合并急性心力衰竭的有效性和安全性。方法:选取2020年12月—2022年12月佛山市顺德新容奇医院收治的82例高血压急症合并急性心力衰竭患者作为研究对象,依据随机数字表法分为对照组与观察组,各41例。对照组采用常规治疗,观察组在对照组基础上采用重组人脑利钠肽联合沙库巴曲缬沙坦序贯治疗。比较两组心功能指标、临床疗效、不良反应发生情况、再入院率。结果:治疗后,两组N末端B型利钠肽原水平、左心室舒张末期内径低于治疗前,且观察组低于对照组,左室射血分数高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05)。观察组治疗总有效率高于对照组,差异有统计学意义(P=0.005)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。观察组再入院率低于对照组,差异有统计学意义(P=0.007)。结论:重组人脑利钠肽联合沙库巴曲缬沙坦治疗高血压急症合并急性心力衰竭的效果显著,可改善患者心功能,降低再住院率,且未增加不良反应发生率。

Objective:To explore the efficacy and safety of recombinant human brain natriuretic peptide combined with sacubitril and valsartan in the treatment of hypertensive emergencies combined with acute heart failure.Methods:A total of 82 patients with hypertensive emergencies combined with acute heart failure who received cardiac valve replacement in Shunde New Rongqi Hospital from December 2020 to December 2022 were selected as the study subjects.They were divided into control group and observation group according to random number table method,with 41 cases in each group.The control group adopted conventional therapy and the observation group adopted sequential therapy of recombinant human brain natriuretic peptide combined with sacubitril valsartan on the basis of control group.The cardiac function indicators,clinical efficacy,incidence of adverse reactions,and readmission rate of two groups were compared.Results:After treatment,the N-terminal B-type natriuretic peptide level and left ventricular end-diastolic diameter in the two groups were lower than those before treatment,and these indexes in the observation group were lower than those in the control group,and the left ventricular ejection fraction in the two groups was higher than that before treatment,and the index in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05).The total effective rate of treatment in the observation group was higher than that in the control group,and the difference was statistically significant(P=0.005).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).The readmission rate in the observation group was lower than that in the control group,and the difference was statistically significant(P=0.007).Conclusion:The combination of recombinant human brain natriuretic peptide and sacubitril valsartan has a significant effect in the treatment of hypertensive emergencies combined with acute heart failure,improving patient cardiac function without increasing the incidence of adverse reactions..